Price
321.3
+0.14%52W Range
Market Cap
₹14,564.16 Cr
Traded: ₹82.79 Cr (0.57%) 0.0x
Free Float: ₹4,727.53 Cr (1.75% of FF traded)
Volume · 60D trend
25.97 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +13.0% | +16.0% | +17.0% | -- | +20.0% | Accelerating |
| ROE | +17.0% | +17.0% | +16.0% | -- | -- | Stable |
| Return | +21.0% | +33.0% | +39.0% | +70.0% | -- | Accelerating |
| Profit | +18.0% | +12.0% | +16.0% | -- | +48.0% | Accelerating |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 841 | 856 | 754 | 720 | 620 | 708 | 682 | 642 | 591 | 560 | 586 | 531 | 500 | 486 | 480 | 453 |
| Expenses | 628 | 661 | 594 | 576 | 520 | 582 | 543 | 495 | 462 | 450 | 453 | 417 | 398 | 376 | 403 | 372 |
| Operating Profit | 213 | 195 | 161 | 144 | 100 | 127 | 139 | 147 | 128 | 110 | 133 | 114 | 102 | 110 | 77 | 80 |
| OPM % | 25.0% | 23.0% | 21.0% | 20.0% | 16.0% | 18.0% | 20.0% | 23.0% | 22.0% | 20.0% | 23.0% | 21.0% | 20.0% | 23.0% | 16.0% | 18.0% |
| Other Income | 25 | 35 | 20 | 22 | 6 | 15 | 28 | 0 | 15 | 17 | 5 | 19 | 10 | 11 | 18 | 14 |
| Interest | 7 | 6 | 6 | 6 | 6 | 3 | 3 | 3 | 3 | 5 | 3 | 2 | 2 | 2 | 2 | 3 |
| Depreciation | 25 | 24 | 24 | 27 | 23 | 23 | 21 | 20 | 20 | 21 | 22 | 18 | 14 | 14 | 13 | 14 |
| Profit Before Tax | 207 | 200 | 151 | 133 | 77 | 116 | 143 | 125 | 120 | 100 | 113 | 114 | 97 | 104 | 79 | 78 |
| Tax % | 23.0% | 25.0% | 25.0% | 26.0% | 24.0% | 22.0% | 27.0% | 22.0% | 26.0% | 23.0% | 26.0% | 26.0% | 27.0% | 21.0% | 21.0% | 23.0% |
| Net Profit | 159 | 149 | 114 | 99 | 58 | 91 | 105 | 98 | 89 | 78 | 83 | 84 | 70 | 83 | 62 | 60 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 3.5 | 3.3 | 2.5 | 2.2 | 1.3 | 2.0 | 2.3 | 2.1 | 2.0 | 1.7 | 1.8 | 1.8 | 1.5 | 1.8 | 1.6 | 1.5 |
| Sales Growth (YoY) | 35.6% | 20.9% | 10.6% | 12.2% | 4.9% | 26.4% | 16.4% | 20.9% | 18.2% | 15.2% | 22.1% | 17.2% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -1.8% | 13.5% | 4.7% | 16.1% | -12.4% | 3.8% | 6.2% | 8.6% | 5.5% | -4.4% | 10.4% | 6.2% | 2.9% | 1.3% | 6.0% | -- |
| OP Growth (YoY) | 113.0% | 53.5% | 15.8% | -2.0% | -21.9% | 15.5% | 4.5% | 28.9% | 25.5% | 0.0% | 72.7% | 42.5% | -- | -- | -- | -- |
| OP Growth (QoQ) | 9.2% | 21.1% | 11.8% | 44.0% | -21.3% | -8.6% | -5.4% | 14.8% | 16.4% | -17.3% | 16.7% | 11.8% | -7.3% | 42.9% | -3.8% | -- |
| Profit Growth (YoY) | -- | 64.0% | 8.0% | 2.0% | -34.0% | 16.0% | 26.0% | 16.0% | 29.0% | -4.0% | 31.0% | 36.0% | 15.0% | 191.0% | 31.0% | 35.0% |
| EPS Growth (YoY) | 169.0% | 63.5% | 8.2% | 1.9% | -34.2% | 15.6% | 25.5% | 15.8% | 28.9% | -4.4% | 17.2% | 21.9% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 6.1% | 30.8% | 15.2% | 68.2% | -35.5% | -13.4% | 8.4% | 8.7% | 13.3% | -6.0% | 0.0% | 21.1% | -16.0% | 15.3% | 4.0% | -- |
| OP Margin | 25.3% | 22.8% | 21.4% | 20.0% | 16.1% | 17.9% | 20.4% | 22.9% | 21.7% | 19.6% | 22.7% | 21.5% | 20.4% | 22.6% | 16.0% | 17.7% |
| Net Margin | 18.9% | 17.4% | 15.1% | 13.8% | 9.3% | 12.8% | 15.4% | 15.3% | 15.1% | 13.9% | 14.2% | 15.8% | 14.0% | 17.1% | 12.9% | 13.3% |
| Material Cost % | -- | 45.6% | 41.9% | 42.8% | 42.2% | 45.9% | 43.8% | 40.3% | 44.3% | 48.2% | 46.5% | 47.6% | 48.5% | 50.2% | 49.9% | 49.3% |
| Employee Cost % | -- | 12.5% | 14.8% | 14.4% | 15.9% | 13.7% | 13.0% | 13.1% | 13.6% | 14.2% | 12.7% | 13.4% | 13.7% | 12.5% | 13.0% | 13.2% |
| P/S | 4.59 | 4.29 | 3.56 | 2.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 28.16 | 30.22 | 27.67 | 22.38 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 4.82 | 4.18 | 3.71 | 2.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Transcript of Investors/Analyst meet on Q1 FY 27 Financial Results
Audio Recording of investor(s)/analyst(s) meet Conference Call on Q1 FY 27 Financial Results
Newspaper Publication for Unaudited Financial Results for the quarter ended June 30, 2026
Investor Presentation Q1 FY 27
The Board in its meeting held on 12 August 2026 approved Financial Results for the quarter ended June 30, 2026
Press Release for Financial Results Q1 FY 27
The Board in its meeting held on 12 August 2026 approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026
Please find attached herewith the Annual Report for the Financial Year 2025-26
Please find enclosed the BRSR
Notice of the 34th Annual General Meeting of the Company proposed to be held on 27 August 2026
Second 100 Day Campaign - "Saksham Niveshak" Phase IV
Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2026
Marksans Pharma signed a definitive agreement to acquire 100 percent share capital of a German based Company namely ABCnow GmbH
The Board in its meeting approved the AGM related matters and fixed 27 August 2026 as the AGM of the Company
The Board of Directors of Marksans Pharma Limited in its meeting held on 3 July 2026 fixed 27 August 2026 as the Annual General Meeting.
20 August 2026 is fixed as Record Date for payment of dividend.
Machine Readable Form/Legible copy of Financial Results
Intimation of Closure of Trading Window for the quarter ended June 30, 2026
Campaign for KYC and other related updations and shareholders engagement to prevent transfer of unclaimed dividend to IEPF
Update on acquisition of QliniQ B.V.
India Ratings and Research has revised the outlook for the Company''s bank loan facilities to Positive from Stable
Intimation of schedule for Virtual Investors Conference
Campaign for KYC and other related updations and shareholders engagement to prevent transfer of unclaimed dividend to IEPF
Press Release titled Marksans Pharma Ltd. to acquire 100 percent of Netherland based QliniQ B.V., strengthening presence in European Markets
ASCR under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year 31, March 2026
Newspaper publication of Audited Financial Results for the financial year ended 31 March, 2026
Audio Recording of investor(s) / analyst(s) meet Conference Call on Q4 FY26 Financial Results
Outcome of Board Meeting held on 26 May, 2026
Marksans Pharma Limited Press Release on Q4 FY26 Results
Investors Presentation Q4 FY26
The Board has recommended Dividend of Rs. 0.90 per share subject to approval of Shareholders at ensuing Annual General Meeting
Audited Financial Results for the quarter and year ended 31 March, 2026
Intimation of Grant of stock options under Marksans Employee Stock Option Scheme 2024
The Company has scheduled a conference call for analysts and investors on Wednesday, May 27, 2026 at 04:30 PM (IST) to discuss the Audited Financial Results (Standalone and Consolidated) ....
Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve Audited Standalone and Consolidated ....
Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2026
USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx)
Intimation of Closure of Trading Window for Quarter and Year ending March 31, 2026
Newspaper publication regarding opening of special window for re-lodgement of the transfer request for physical shares
Public notice regarding opening of Special Window for Re-lodgement of Transfer Requests of Physical Shares for information of Shareholders of the Company
Officials of the Company will be participating in Investec India Promoter & Founder Conference 2026
Marksans Pharma Limited submits transcript of Investors/Analyst meet on Q3 9M FY 26 Unaudited Financial Results held on February 06, 2026
Audio Recording of investor(s) / analyst(s) meet Conference Call on Q3 & 9M FY26 Financial Results
Newspaper Publication of Un-Audited Financial Results for the Quarter and Nine months ended 31 December, 2025
Press Release regarding unaudited financial results for Q3 FY 26
Marksans Investors Presentation Q3 and 9M FY 26
Unaudited financial results for the quarter and nine months ended 31 December, 2025
Outcome of Board Meeting - Unaudited Financial Results for the quarter and nine months ended 31 December, 2025
Incorporation of two new wholly owned subsidiary Companies
The Company has scheduled a conference call for analysts and investors on Friday, February 06, 2026 at 04:00 PM (IST) to discuss the Unaudited Financial Results (Standalone and Consolidated) ....
Annual Reports
15Credit Ratings
6Concalls
28Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Jun 2024
30 Jun 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023Jun 2023
30 Jun 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022Jun 2022
30 Jun 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021May 2021
31 May 2021Feb 2021
28 Feb 2021Nov 2020
30 Nov 2020Aug 2020
31 Aug 2020Jun 2020
30 Jun 2020Feb 2020
29 Feb 2020Aug 2019
31 Aug 2019Aug 2019
31 Aug 2019Held by ETFs
2 ETFs hold marksans · sorted by weight
Held by Mutual Funds
12 schemes hold marksans · sorted by weight